REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. and Encourages Investors to Contact the Firm Before September 22nd

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for allegedly making false and misleading statements regarding the IGNYTE trial, which led to investor losses during the specified class period from November 22, 2024, to July 21, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court District of Massachusetts on behalf of all individuals and entities who purchased Replimune securities during the class period [2]. - Investors have until September 22, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The lawsuit claims that defendants overstated the IGNYTE trial's prospects, resulting in the FDA deeming the trial inadequate and not well-controlled [4]. Group 2: Investor Information - Investors who suffered losses and are long-term stockholders are encouraged to contact the law firm for more information regarding their rights and potential claims [5]. - The law firm, Bragar Eagel & Squire, P.C., specializes in representing individual and institutional investors in complex litigation [6].